Monday, 19 February 2019: Plasma proteins are likely to be used in replacement therapies to treat deficiency of coagulation factor in terms of hemostasis. This deficiency can occur due to autoimmune disorder or it can be genetic. It can also occur as complication of cancer. Hemostasis can be defined as a process in humans, which can cause bleeding to stop. In this process, the blood is expected to coagulate from liquid form to gel. Lack of coagulation factor can lead to blood loss during accidents or medical procedures. Plasma protein can balance the deficiency and support coagulation of blood.
Albumin to Support Diagnosis of Diabetes
Major product variants of plasma protein therapeutic are immunoglobulin, albumin, and factor viii. Albumin segment is expected to witness significant market share in coming years attributed to increasing use in diagnostic procedure for hypoalbuminemia. Hepatitis B and liver cirrhosis are likely to cause medical sign called hypoalbuminemia in humans. Rising cases of disease across the globe is anticipated to propel product demand in coming years. Most companies and research institutes are investing in research activities to find advanced applications of the product in healthcare sector. For instance, a group of scientists at National Chemical Laboratory in India recently discovered that measuring level of free albumin and albumin attached to glucose molecules in blood can help diagnose diabetes in better manner. The level of glucose bound hemoglobin can efficiently explain diabetic condition in individuals.
Market Insights
The global plasma protein therapeutic market is anticipated to reach USD 33.15 billion by 2025, according to a report by Grand View Research, Inc. Advent of novel products offering easy plasma sample extraction technique can augment market growth. These products can also offer improved efficacy in clinical procedures and impel growth of market. Rising demand for albumin and increasing use of immunoglobulin in developed countries can drive the market in coming years. Manufacturing companies are expected to focus on development of advanced products to treat various neurological disorders including post-polio syndrome, Myasthenia gravis, and neuropathic pain. High demand for immunoglobulins, protein mainly derived from plasma cells to neutralize pathogens such as viruses and bacteria can stimulate market growth during the forecast period (2014 to 2025).
Some of the leading companies operating in the market for plasma protein therapeutic market are Shire Plc, CSL Behring LLC, Grifols S.A., Octapharma AG, and Bayer AG.
No comments:
Post a Comment